CELC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Celcuity Inc (CELC) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show bullish momentum, insider selling and weak financial performance raise concerns. The lack of strong proprietary trading signals and a mixed options sentiment further suggest a cautious approach.
The stock shows bullish momentum with MACD positively expanding, RSI in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at 114.864 and 118.141, with support at 104.256 and 100.979. However, the stock trend analysis predicts a slight decline in the next week and month.
Wells Fargo initiated coverage with an Overweight rating and a $126 price target, citing gedatolisib's market opportunity.
The $130 strike call option recorded high trading volume, reflecting investor optimism.
Insider selling has increased by 657.10% over the last month, signaling potential lack of confidence from management.
Financial performance remains weak, with no revenue growth and a net loss of -$43.8M in Q3
Hedge funds remain neutral, and no significant trading trends were observed.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net loss of -$43.8M, though the loss improved by 47.03% YoY. EPS also improved to -0.92, up 31.43% YoY. Gross margin remains at 0%.
Wells Fargo initiated coverage with an Overweight rating and a $126 price target, citing gedatolisib's potential in breast cancer and metastatic castration-resistant prostate cancer. Analysts believe the current stock price undervalues this opportunity.
